[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6374 Introduced in House (IH)]
<DOC>
117th CONGRESS
2d Session
H. R. 6374
To implement the recommendations of the Inspector General of the
Department of Defense with respect to mitigation of foreign suppliers
in the pharmaceutical supply chain of the Department of Defense.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
January 12, 2022
Ms. Houlahan (for herself and Mr. Meijer) introduced the following
bill; which was referred to the Committee on Armed Services
_______________________________________________________________________
A BILL
To implement the recommendations of the Inspector General of the
Department of Defense with respect to mitigation of foreign suppliers
in the pharmaceutical supply chain of the Department of Defense.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Strengthening Supply Chains for
Servicemembers and Security Act''.
SEC. 2. RISK MANAGEMENT FOR DEPARTMENT OF DEFENSE SUPPLY CHAINS.
(a) Risk Management for All Department of Defense Supply Chains.--
Not later than 180 days after the date of the enactment of this Act,
the Under Secretary of Defense for Acquisition and Sustainment shall--
(1) develop and issue implementing guidance for risk
management for Department of Defense supply chains for materiel
for the Department, including pharmaceuticals;
(2) identify, in coordination with the Commissioner of Food
and Drugs, supply chain information gaps regarding reliance on
foreign suppliers of drugs, including active pharmaceutical
ingredients and final drug products; and
(3) submit to Congress a report regarding--
(A) existing information streams, if any, that may
be used to assess the reliance by the Department of
Defense on high-risk foreign suppliers of drugs;
(B) vulnerabilities in the drug supply chains of
the Department of Defense; and
(C) any recommendations to address--
(i) information gaps identified under
paragraph (2); and
(ii) any risks related to such reliance on
foreign suppliers.
(b) Risk Management for Department of Defense Pharmaceutical Supply
Chain.--The Director of the Defense Health Agency shall--
(1) not later than one year after the issuance of the
guidance required by subsection (a)(1), develop and publish
implementing guidance for risk management for the Department of
Defense supply chain for pharmaceuticals; and
(2) establish a working group--
(A) to assess risks to the pharmaceutical supply
chain;
(B) to identify the pharmaceuticals most critical
to beneficiary care at military treatment facilities;
and
(C) to establish policies for allocating scarce
pharmaceutical resources in case of a supply
disruption.
(c) Responsiveness Testing of Defense Logistics Agency
Pharmaceutical Contracts.--The Director of the Defense Logistics Agency
shall modify Defense Logistics Agency Instructions 5025.03 and
3110.01--
(1) to require Defense Logistics Agency Troop Support to
coordinate annually with customers in the military departments
to conduct responsiveness testing of the Defense Logistics
Agency's contingency contracts for pharmaceuticals; and
(2) to include the results of that testing, as reported by
customers in the military departments, in the annual reports of
the Warstopper Program.
<all>